Clinical trials: Oral Phase
Acute Pain
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VX-708 in healthy participants.
- Trial name
- NCT05347394
- Testing
- VX-708
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Candida Vulvovaginitis
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and…
- Trial name
- DOVE (NCT03253094)
- Testing
- Fluconazole, SCY-078
- Where
- 25 sites in United States
- Volunteers
- 186 people
- Sponsor
- Scynexis, Inc.
Ulcerative Colitis, Ulcerative Colitis Acute
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo).
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
- Trial name
- PL8177-205 (NCT05466890)
- Testing
- PL8177
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Palatin Technologies, Inc
Post-COVID Condition, Fatigue Symptom
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID).
- Trial name
- CLEAR-LC (NCT06597396)
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Beth Israel Deaconess Medical Center
Sarcoma, Kaposi, HIV Infections
A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00002188
- Testing
- Alitretinoin
- Volunteers
- 27 people
- Sponsor
- Anderson Clinical Research
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
This phase II trial studies how well celecoxib works through surgery and radiation therapy in treating patients with head and neck cancer that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma
- Trial name
- NCT04162873
- Testing
- Celecoxib, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Utah
Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.
- Conditions
- Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT03381183
- Testing
- Durvalumab, IRX-2 Regimen
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Follicular Lymphoma (FL)
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all…
- Trial name
- EPCORE FL-1 (NCT05409066)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 273 sites in United States, Argentina and 28 more
- Volunteers
- 549 people
- Sponsor
- Genmab
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.
- Trial name
- NCT02489513
- Testing
- [14C]-AG-120
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Healthy
Single and Multiple Ascending Doses of AZD1981 in Japan
The purpose of this study is to study safety, tolerability and pharmacokinetics of AZD1981 in healthy Japanese subjects
- Trial name
- JSAD/JMAD (NCT00698282)
- Testing
- AZD1981
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Fever
A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers
This is a single dose study that will evaluate the efficacy and safety of a Fixed Dose Combination Ibuprofen 250 mg/ Acetaminophen 500 mg tablet in healthy male patients with fever.
- Trial name
- NCT02761980
- Testing
- Ibuprofen 250 mg / Acetaminophen 500 mg, Ibuprofen 250 mg, Acetaminophen 500 mg
- Where
- United States
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Pfizer
Uncomplicated Urinary Tract Infection, Cystitis
Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis
The purpose of this study is to evaluate the safety and efficacy of oral omadacycline as compared to oral nitrofurantoin in the treatment of female adults with cystitis.
- Trial name
- NCT03425396
- Testing
- Omadacycline tablets, Nitrofurantoin capsules
- Where
- 23 sites in United States
- Volunteers
- 225 people
- Sponsor
- Paratek Pharmaceuticals Inc
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Solid Tumours
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Itraconazole and Fluconazole on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02093728
- Testing
- selumetinib, itraconazole, fluconazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Trigeminal Neuralgia
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice.
- Trial name
- NCT05217628
- Testing
- Basimglurant
- Where
- 34 sites in United States, Denmark and 6 more
- Volunteers
- 166 people
- Sponsor
- Noema Pharma AG
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
This study will evaluate whether adding rimegepant to standard neoadjuvant chemoimmunotherapy can improve treatment response in patients with primary or recurrent oral or oropharyngeal squamous cell carcinoma who are planned to…
- Trial name
- NCT07812467
- Testing
- Rimegepant, Tislelizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Hypertriglyceridemia, Type 2 Diabetes
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes
- Trial name
- TRIAGE (NCT04365400)
- Testing
- DS102
- Where
- 56 sites in United States, Georgia and 4 more
- Volunteers
- 233 people
- Sponsor
- Afimmune
Respiratory Syncytial Virus Infections
Safety Study of Oral BTA9881 to Treat RSV Infection
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects
- Trial name
- NCT00504907
- Testing
- BTA9881
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Advanced Cancer, Advanced Solid Tumor
Oral Administration of STC-15 in Subjects With Advanced Malignancies
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer
- Trial name
- NCT05584111
- Testing
- STC-15
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- STORM Therapeutics LTD
Diabetes
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers
The purpose of this study is to determine (1) whether ZYGK1 is safe and well tolerated, (2) the pharmacokinetics (what body does to ZYGK1) and (3) pharmacodynamics (what drugs does to the body) in the healthy and diabetic subject.
- Trial name
- NCT01472809
- Testing
- ZYGK1
- Where
- India
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.